
On May 4, 2022, BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation of a poster titled, "MSC-NTF Derived Small Extracellular Vesicles Display Superior Macrophage Immunomodulation Compared with Vesicles Derived from Naïve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, California. The poster will be presented by Kim Thacker, MD, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.